71 West Capital Partners Takes Position in Bristol Myers Squibb Company $BMY

71 West Capital Partners acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 10,500 shares of the biopharmaceutical company’s stock, valued at approximately $566,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. waypoint wealth counsel acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth about $1,194,000. Life Cycle Investment Partners Ltd acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $34,406,000. Axxcess Wealth Management LLC raised its holdings in Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after acquiring an additional 21,196 shares in the last quarter. Daytona Street Capital LLC purchased a new position in Bristol Myers Squibb in the fourth quarter worth approximately $1,362,000. Finally, Pensionfund Sabic acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $1,845,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Guggenheim restated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Barclays started coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. Finally, UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Down 0.6%

Shares of NYSE BMY opened at $55.91 on Wednesday. The business has a 50-day moving average price of $57.59 and a 200 day moving average price of $57.03. The stock has a market cap of $114.18 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.